← Back to headlines
Nektar Outlines REZPEG Phase III Timeline
Nektar Therapeutics has provided a timeline for its REZPEG Phase III clinical trial, anticipating data by mid-2028 and a Biologics License Application (BLA) plan for 2029.
14 Aug, 03:27 — 14 Aug, 03:27
Sources
Showing 1 of 1 sources
Related Stories
Selena Gomez Sued by Investors for Alleged Fraud in Mental Health Startup
27m ago
Nvidia Discloses $21 Billion Stake in SpaceX and $30 Billion in Intel
37m ago
Consortium Seals $1.9 Billion Investment in Liverpool FC, Amit Bhatia Named Vice-Chairman
39m ago
Berkshire Hathaway Increases Stakes in Alphabet, Delta, and Housing Market
48m ago